Foster City Journalist Profile

Articles

Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years

2 months ago | academic.oup.com | Foster City |Hôpital Louis

Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination with an optimized background regimen (OBR). Resistance analyses conducted after 2 years of lenacapavir treatment in the phase 2/3 CAPELLA study are described. CAPELLA enrolled viremic HTE PWH with resistance to 2 or more drugs per class in at least 3 of the 4 main drug classes.
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir

Jan 24, 2025 | academic.oup.com | Foster City

HIV-1 treatment guidelines recommend integrase strand-transfer inhibitor (INSTI)-based regimens for both initial and switch ART in people with HIV (PWH).1–3 As novels agents are introduced for HIV-1 treatment and pre-exposure prophylaxis (PrEP), it is important to understand resistance emergence at virological failures and seroconversions, as cross-resistance can limit subsequent treatment options.
Single-cell sequencing of full-length transcripts and T-cell receptors with automated high-throughput Smart-seq3 - BMC Genomics

Nov 21, 2024 | bmcgenomics.biomedcentral.com | Foster City

Peripheral whole blood was collected from two healthy donors (Donor 1, ID RB1460; Donor 2, ID RB1651) in ethylenediaminetetraacetic acid (EDTA)-coated tubes by BioIVT (Colmar, PA, USA) [49]. Upon receipt, peripheral blood mononuclear cells (PBMCs) were isolated using SepMate tubes (STEMCELL Technologies, Cat. #85450) following the manufacturer’s instructions. The isolated PBMCs were resuspended in RPMI 1640 medium (Gibco, Cat. #11875093) supplemented with 5% human serum (Sigma, Cat.
Employing effective recruitment and retention strategies to engage a diverse pediatric population in genomics research

Nov 19, 2024 | cell.com | Foster City |Albert Einstein College |Carol Horowitz

1Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA 3Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA 4Department of Pediatrics, Division of Pediatric Genetic Medicine, Children’s Hospital at Montefiore/Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA 5Department of...
Senior Director, US HIV Prevention Launch Hub Lead

Nov 16, 2024 | cafepharma.com | Foster City

Senior Director, US HIV Prevention Launch Hub Lead Submitted by admin on November 16, 2024 - 4:20pm Senior Director, US HIV Prevention Launch Hub Lead United States - California - Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Foster City, California 37° 31' 5.0844" N, 122° 20' 41.1396" W US
Early Viral Dynamics Predict HIV Post-Treatment Control After Analytic Treatment Interruption

Nov 8, 2024 | academic.oup.com | Foster City

A key research priority for developing an HIV cure strategy is to define the viral dynamics and biomarkers associated with sustained post-treatment control. The ability to predict the likelihood of sustained post-treatment control or non-control could minimize the time off antiretroviral therapy (ART) for those destined to not control and anticipate longer periods off ART for those destined to control.
Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals

Oct 19, 2024 | academic.oup.com | Foster City

COVID-19 remains a major public health concern, with continued resurgences of cases and substantial risk of mortality for hospitalized patients. Remdesivir has become standard-of-care for hospitalized COVID-19 patients. Given the continued evolution of the disease, clinical management relies on evidence from the current endemic period.
Integrating external summary information in the presence of prior probability shift: an application to assessing essential hypertension

Sep 9, 2024 | academic.oup.com | Foster City

Recent years have witnessed a rise in the popularity of information integration without sharing of raw data. By leveraging and incorporating summary information from external sources, internal studies can achieve enhanced estimation efficiency and prediction accuracy. However, a noteworthy challenge in utilizing summary-level information is accommodating the inherent heterogeneity across diverse data sources.
Side Effects, Uses, Dosage, Interactions, Warnings

Aug 28, 2024 | rxlist.com | Foster City

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 8/28/2024 Related Drugs Actigall Ocaliva Reltone Urso What Is Livdelzi?
HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies

Mar 14, 2024 | academic.oup.com | Foster City |De Boer

Oral pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) has high efficacy against HIV-1 acquisition. Seventy-two prospective studies of daily oral F/TDF PrEP were conducted to evaluate HIV-1 incidence, drug resistance, adherence, and bone and renal safety in diverse settings. HIV-1 incidence was calculated from incident HIV-1 diagnoses after PrEP initiation and within 60 days of discontinuation.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Foster City

Articles

Resistance Analyses in Heavily Treatment-Experienced People with HIV Treated with the Novel HIV Capsid Inhibitor Lenacapavir After 2 years

Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir

Single-cell sequencing of full-length transcripts and T-cell receptors with automated high-throughput Smart-seq3 - BMC Genomics

Employing effective recruitment and retention strategies to engage a diverse pediatric population in genomics research

Senior Director, US HIV Prevention Launch Hub Lead

Early Viral Dynamics Predict HIV Post-Treatment Control After Analytic Treatment Interruption

Management of vulnerable patients hospitalized for COVID-19 with remdesivir: a retrospective comparative effectiveness study of mortality in US hospitals

Integrating external summary information in the presence of prior probability shift: an application to assessing essential hypertension

Side Effects, Uses, Dosage, Interactions, Warnings

HIV-1 Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-Exposure Prophylaxis: Pooled Analysis From 72 Global Studies

Contact details

Emails

Socials & Sites